The Big Ten Cancer Research Consortium (BTCRC) arose from the fast-changing personalized medicine environment amid diminishing research opportunities for junior faculty and increasing demands to pre-screen large populations in order to identify small, molecularly-enriched subsets.
Expedited contracting by virtue of membership
Planned consolidated IRB review
Organized clinical trial working groups
Ability to share specimens with clinically annotated data
Avenue for development of junior faculty
Opportunity to quickly open trials across 11 academic institutions